Breaking News Instant updates and real-time market news.

AGN

Allergan

$164.85

-8.98 (-5.17%)

10:52
10/30/18
10/30
10:52
10/30/18
10:52

Saunders says shares 'inexpensive,' says 'looking opportunistically' at buybacks

Allergan CEO Brent Saunders is being interviewed on CNBC.

  • 30

    Oct

  • 12

    Nov

AGN Allergan
$164.85

-8.98 (-5.17%)

10/29/18
MSCO
10/29/18
NO CHANGE
MSCO
Equal Weight
Morgan Stanley sees little impact to Regeneron from competitor data at AAO
Morgan Stanley analyst Matthew Harrison noted that data was presented at the American Academy of Ophthalmology's annual meeting for three potential competitors to Regeneron's (REGN) Eylea - Allergan's (AGN) abicipar pegol, Novartis' (NVS) brolucizumab and Roche's (RHHBY) faricimab. Following the presentations, his view on abicipar and brolucizumab is unchanged and he awaits further late-stage data from faricimab, said Harrison, who sees little impact to Regeneron based on the new data. He maintains an Equal Weight rating on Regeneron shares.
10/29/18
PIPR
10/29/18
NO CHANGE
PIPR
Neutral
Piper sees Amgen's Aimovig pressuring Allergan's Botox in near term
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Amgen (AMGN) and Neutral rating on Allergan (AGN) after his firm's Overweight based on feedback from a migraine survey fielded by his firm's partner Spherix Global Insights. The analyst is "struck by the progress" Amgen has made just months into Aimovig's launch, specifically on sales coverage, message delivery and overall credibility with physicians. It appears that Allergan's Botox "could be in for some pressure in the near term at the direct hands" of Amgen's Aimovig, Raymond tells investors in a research note titled "Aiming for Aimovig; New Migraine Survey Indicates Aimovig the Star of the Show." Doctors are projecting peak Aimovig share of 49% and 29% for chronic and episodic patients respectively, which infers peak U.S. revenue for the drug at $3.3B, the analyst says. Further, he notes that of the 98 high volume migraine specialists surveyed, 43% versus 29% agreed with the statement: "I am more likely to prescribe Aimovig over Botox due to access to patient assistance program."
10/18/18
WELS
10/18/18
NO CHANGE
WELS
Outperform
Allergan migraine update 'very positive' news, says Wells Fargo
Allergan yesterday announced the completion of two positive safety and tolerability studies for its oral anti-CGRP acute migraine treatment, ubrogepant, Wells Fargo analyst David Maris tells investors in a research note titled ": Effective? Check. Safe? Check. Oral Migraine Drug Clears Key Hurdle." The data showcase what Allergan has reiterated all along, that ubrogepant has shown to provide triptan-like efficacy in treating acute migraines with a lower adverse event profile and an absence of drug-induced elevated liver enzyme levels, Maris contends. The analyst, who currently models $175M in sales for ubrogepant in 2022, believes many on the Street are underestimating Allergan and ubrogepant "given the past concerns over hepatic safety that do not appear to be evident." Ubrogepant may have $1B-plus sales potential if approved, says Maris. He finds yesterday's safety update as "very positive" news for Allergan and keeps an Outperform rating on the stock.
10/18/18
MZHO
10/18/18
NO CHANGE
Target $210
MZHO
Buy
Allergan reported clean safety profile for migraine treatment, says Mizuho
Allergan yesterday reported a clean safety profile in two safety studies of ubrogepant for the treatment of acute migraine, Mizuho analyst Irina Koffler tells investors in a research note. The analyst believes these results may also de-risk atogepant, Allergan's second follow-on oral CGRP program in migraine prophylaxis. She reiterates a Buy rating on the shares with a $210 price target.

TODAY'S FREE FLY STORIES

MGA

Magna

$54.61

2.015 (3.83%)

15:04
02/22/19
02/22
15:04
02/22/19
15:04
Downgrade
Magna rating change  »

Magna downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

LTRPA

Liberty TripAdvisor

$16.20

0.31 (1.95%)

15:04
02/22/19
02/22
15:04
02/22/19
15:04
Options
Liberty TripAdvisor options imply 4.8% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$278.32

0.89 (0.32%)

14:59
02/22/19
02/22
14:59
02/22/19
14:59
Periodicals
U.S. Treasury Secretary says U.S, China reach pact on currency issues, CNBC says »

Steven Mnuchin, U.S.…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.32

0.89 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:55
02/22/19
02/22
14:55
02/22/19
14:55
General news
Fed's Bullard doesn't want to be shrinking the balance sheet and cutting rates »

Fed's Bullard…

ALXN

Alexion

$128.46

0.9 (0.71%)

14:52
02/22/19
02/22
14:52
02/22/19
14:52
Hot Stocks
Alexion says FDA grants priority review and accepts sBLA of Soliris »

Alexion Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 20

    Mar

14:50
02/22/19
02/22
14:50
02/22/19
14:50
Conference/Events
Senate Energy & Natural Resources Committee to hold a hearing »

The Committee holds a…

JMEI

Jumei

$2.68

0.19 (7.63%)

14:49
02/22/19
02/22
14:49
02/22/19
14:49
Options
Jumei options imply 7.1% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGR

Avangrid

$48.84

-0.06 (-0.12%)

14:42
02/22/19
02/22
14:42
02/22/19
14:42
Conference/Events
Avangrid to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 04

    Mar

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$278.77

1.34 (0.48%)

14:42
02/22/19
02/22
14:42
02/22/19
14:42
Periodicals
Xi tells Trump both sides will redouble efforts to come to trade pact, CNBC says »

In a letter to U.S.…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.77

1.34 (0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRPL

Purple

$5.74

0.045 (0.79%)

14:40
02/22/19
02/22
14:40
02/22/19
14:40
Conference/Events
Purple to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

14:40
02/22/19
02/22
14:40
02/22/19
14:40
General news
Fed's Quarles confirmed the FOMC's decision to maintain an "ample" reserve balance »

Fed's Quarles…

TXN

Texas Instruments

$107.25

0.64 (0.60%)

14:35
02/22/19
02/22
14:35
02/22/19
14:35
Syndicate
Breaking Syndicate news story on Texas Instruments »

Texas Instruments files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

PDVW

pdvWireless

$46.00

5.105 (12.48%)

14:30
02/22/19
02/22
14:30
02/22/19
14:30
Hot Stocks
pdvWireless move higher attributed to FCC proposed rulemaking notice »

Shares of pdvWireless are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NIO

NIO Inc.

$8.01

0.395 (5.19%)

14:25
02/22/19
02/22
14:25
02/22/19
14:25
Options
NIO Inc call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Mar

14:25
02/22/19
02/22
14:25
02/22/19
14:25
General news
Action Economics Survey results: »

Action Economics Survey…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
02/22/19
02/22
14:17
02/22/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
02/22/19
02/22
14:16
02/22/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MUFG

Mitsubishi UFJ

$5.27

-0.02 (-0.38%)

14:15
02/22/19
02/22
14:15
02/22/19
14:15
Hot Stocks
OCC issues cease and desist order against MUFG Bank over BSA violation »

The Office of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

XOG

Extraction Oil & Gas

$4.64

0.83 (21.78%)

14:13
02/22/19
02/22
14:13
02/22/19
14:13
Recommendations
Extraction Oil & Gas analyst commentary  »

Extraction Oil & Gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FXI

iShares China Large-Cap ETF

$44.14

0.73 (1.68%)

14:10
02/22/19
02/22
14:10
02/22/19
14:10
Options
Size option spreads in iShares China Fund as the trade-hope rally continues »

Size option spreads in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$278.82

1.39 (0.50%)

14:09
02/22/19
02/22
14:09
02/22/19
14:09
Periodicals
China, U.S. remain far apart on intellectual property transfer, CNBC reports »

China has committed to…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.82

1.39 (0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTRN

Citi Trends

$20.69

0.28 (1.37%)

14:06
02/22/19
02/22
14:06
02/22/19
14:06
Initiation
Citi Trends initiated  »

Citi Trends initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Mar

  • 15

    Mar

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$278.82

1.39 (0.50%)

14:04
02/22/19
02/22
14:04
02/22/19
14:04
Periodicals
Breaking Periodicals news story on S&P 500, SPDR S&P 500 ETF Trust »

China agrees to buy $1.2…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.82

1.39 (0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNK

Cinemark

$38.52

1.58 (4.28%)

14:04
02/22/19
02/22
14:04
02/22/19
14:04
Recommendations
Cinemark analyst commentary  »

Cinemark Q4 results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 25

    Feb

  • 11

    Mar

  • 02

    Apr

  • 02

    Apr

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$278.82

1.39 (0.50%)

14:04
02/22/19
02/22
14:04
02/22/19
14:04
Periodicals
Breaking Periodicals news story on S&P 500, SPDR S&P 500 ETF Trust »

U.S., China remain far…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.82

1.39 (0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.